JBIO vs AURA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AURA Captures Institutional Edge (2โ1 Pillars ยท 2โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aura Biosciences, Inc. Common Stock (AURA) driven by superior Growth & Margin, Momentum & Technical while JBIO counters with relative strength in Options & Structure. Fundamentally, JBIO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus AURA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, JBIO sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro) against AURA sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | JBIO | AURA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.0B | $728.6M | Larger Scale | JBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -89.2% | -61.7% | Higher ROE | AURA |
| 52-Week Range Position Momentum | 32% ($10โ$28) | 52% ($5โ$10) | Stronger Trend | AURA |
| Beta / 30D Volatility Risk Regime | 1.35ฮฒ ยท 60% Vol | 0.92ฮฒ ยท 75% Vol | Lower Realized Risk | JBIO |
| Unified Institutional Score Composite Signal | 32.6 / 100 (SELL) | 28.8 / 100 (SELL) | Higher Composite | JBIO |